Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of azacitidine when given together
with cytarabine and mitoxantrone hydrochloride in treating patients with high-risk acute
myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, cytarabine, and
mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either
by killing the cells or by stopping them from dividing. Azacitidine may also help cytarabine
and mitoxantrone hydrochloride work better by making the cancer cells more sensitive to the
drugs